science
GLP-1 Obesity Drugs Generate Higher R&D Returns Than Oncology
Obesity treatments have become the leading driver of pharmaceutical research and development gains, surpassing oncology. A Deloitte partner highlighted concentration risks for companies reliant on these drugs. Plus-size model Ashley Graham described the trend as disheartening for body positivity efforts.
medpagetoday.comAudio version
Tap play to generate a narrated version.
Developing·Limited corroboration so far. This page will refresh as more sources emerge.
Obesity drugs have displaced oncology as the largest contributor to pharmaceutical R&D returns. GLP-1 drugs are used for weight loss and diabetes. While these drugs have become transformative for patients and health systems, they present a concentration risk for pharmaceutical companies, Deloitte Life Sciences and Healthcare Partner Hanno Ronte said.
She called the GLP-1 trend 'a smack in the face' to the body positivity movement. Graham is a mother of three. She has three sons named Isaac, aged 6, and twins Malachi and Roman, aged 4, with her husband Justin Ervin.
Graham and Ervin have been married since August 2010. Graham is a plus-size model who broke through barriers in the fashion world. She covers Marie Claire’s new Motherhood issue, where she shared her views on the effects of the GLP-1 trend on body positivity.
